Royalty Pharma plc
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the second quarter of 2026, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”):
| Name and Title | Action | Adoption/ TerminationDate | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|---|
| Marshall Urist, M.D., Ph.D.Executive Vice President, Research & Investments | Adoption | June 26, 2026 | October 9, 2026 | EPA Shares(2) |
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2)On June 26, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on September 28, 2026 and end on October 9, 2026, providing for the sale of up to 100% of the Class A ordinary shares that may be issued upon settlement of EPAs in August 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.